Fig. 9From: Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironmentThe potential of the signature as an indicator of immunotherapy response in PCa patients. Distribution of PD-1 (A), PD-L1 (B), PD-L2 (C), CTLA4 (D), B7H3 (E), and B7H4 (F) expression in the high and low-risk groups. Kaplan–Meier survival curves for the four patient groups stratified by risk score and PD-1 (G), PD-L1 (H), PD-L2 (I), CTLA4 (J), B7H3 (K), and B7H4 (L) expression. M The response rate to immunotherapy in the TCGA cohort of PCa patients based on the TIDE algorithmBack to article page